Showing results (481-490 of 603) with videos related to

Sort By:
Pageof 61
Research Square|April 17, 2026
Risk of AL Amyloidosis is Associated with Degree of Free Light Chain Elevation and Duration of ExposureAngela Dispenzieri, Maximilian Steinhardt, Eli Muchtar, et al.
British Journal of Haematology|November 20, 2020
Implications of detecting serum monoclonal protein by MASS-fix following stem cell transplantation in multiple myelomaJithma P Abeykoon, David L Murray, Isaiah Murray, et al.
European Journal of Haematology|November 24, 2020
Characterization and prognostic implication of delayed complete response in AL amyloidosisEli Muchtar, Morie A Gertz, Shaji K Kumar, et al.
American Journal of Hematology|July 19, 2020
Refining amyloid complete hematological response: Quantitative serum free light chains superior to ratioEli Muchtar, Morie A Gertz, Martha Q Lacy, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 29, 2025
Dose Delays and Treatment Interruptions Secondary to Ocular Toxicity From BCMA-Directed Antibody Drug Conjugate Therapy in Relapsed Multiple MyelomaMatthew J Rees, Timothy T Xu, Suheil Albert Atallah-Yunes, et al.
American Journal of Hematology|October 4, 2025
Clinical Characteristics, Treatment Responses and Outcomes of Light Chain Multiple MyelomaAbiola Bolarinwa, Saurabh Zanwar, Nadine Abdallah, et al.
Blood Advances|January 30, 2025
Solitary plasmacytoma: single-institution experience, and systematic review and meta-analysis of clinical outcomesCharalampos Charalampous, Jean-Sebastien Claveau, Prashant Kapoor, et al.
Blood Cancer Journal|August 30, 2020
Characteristics of exceptional responders to autologous stem cell transplantation in multiple myelomaAshley Paquin, Alissa Visram, Shaji K Kumar, et al.
Blood Advances|April 13, 2019
Comparison of different techniques to identify cardiac involvement in immunoglobulin light chain (AL) amyloidosisMohammed A Aljama, M Hasib Sidiqi, Angela Dispenzieri, et al.
Blood|June 22, 2011
Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory diseaseMartha Q Lacy, Jacob B Allred, Morie A Gertz, et al.
Pageof 61